Equities analysts expect Celsion Co. (NASDAQ:CLSN) to announce ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Celsion’s earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.15). Celsion reported earnings of $0.32 per share during the same quarter last year, which would indicate a negative year over year growth rate of 178.1%. The firm is expected to announce its next quarterly earnings results on Friday, April 3rd.
On average, analysts expect that Celsion will report full year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($1.05) to ($0.82). For the next year, analysts expect that the company will report earnings of ($0.62) per share, with EPS estimates ranging from ($0.77) to ($0.54). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Celsion.
Celsion (NASDAQ:CLSN) last released its quarterly earnings data on Friday, November 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.05. Celsion had a negative return on equity of 57.46% and a negative net margin of 1,653.20%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million.
Separately, Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd.
Shares of Celsion stock traded up $0.04 on Friday, reaching $1.48. The company’s stock had a trading volume of 17,795 shares, compared to its average volume of 229,145. Celsion has a 52 week low of $1.05 and a 52 week high of $2.63. The firm’s fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $1.73. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $32.49 million, a price-to-earnings ratio of -2.18 and a beta of 1.87.
A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. increased its stake in shares of Celsion Co. (NASDAQ:CLSN) by 5.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 146,332 shares of the biotechnology company’s stock after purchasing an additional 7,070 shares during the period. BlackRock Inc. owned approximately 0.71% of Celsion worth $267,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.95% of the company’s stock.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Recommended Story: Blockchain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.